I've lived solely in the Wuxi New District, in various locations up and down Changjiang North Road. I'd been running for a ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

China has executed a man who killed 35 people by plowing his car into crowds at a sports center in November, in the country’s ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

WuXi STA expects to hire about 500 people in the coming years to support Phase 1 of the manufacturing campus. A Chinese pharmaceutical company is moving forward with plans to build a massive $510 ...

As one of four sub-venues for this year's Chunwan, or Spring Festival Gala, Wuxi in East China's Jiangsu province is pulling ...

WuXi AppTec sells US device testing sites to NAMSA, Notch Therapeutics cuts staff, and Neurizon's ALS drug NUZ-001 faces FDA clinical hold.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

WuXi AppTec is parting ways with its U.S. medical device testing business, selling its two stateside locations to the Ohio-based regulatory consulting firm NAMSA. | The deal includes facilities in ...